Tags

Type your tag names separated by a space and hit enter

[Pentoxifylline and intermittent claudication: critical analysis of clinical trials].
Therapie. 1995 Jan-Feb; 50(1):73-8.T

Abstract

Drug utility in the treatment of intermittent claudication is controversial, mainly because of data heterogeneity and not too obvious benefit in the clinical trials. Pentoxifylline is the world's largest prescribed drug for intermittent claudication. In an attempt to define its benefit in the global care of the claudicants, we have analysed all the randomized double-blind, placebo-controlled trials listed from the international data-bases. Methodology of these trials have been compared with the European and FDA guidelines. In this respect, the 3 best suitable studies are consistent with one other and with a statistical benefit of pentoxifylline on the claudication distances. Although this effect is not truly predictive of the long term benefit-risk ratio of the drug, it seems clinically useful, especially when considering stable patients and when using the drug after previous physical training.

Authors+Show Affiliations

Laboratoires Hoechst, Puteaux, France.No affiliation info available

Pub Type(s)

Clinical Trial
English Abstract
Journal Article
Randomized Controlled Trial
Review

Language

fre

PubMed ID

7754482

Citation

Charansonney, O L., and A Spriet. "[Pentoxifylline and Intermittent Claudication: Critical Analysis of Clinical Trials]." Therapie, vol. 50, no. 1, 1995, pp. 73-8.
Charansonney OL, Spriet A. [Pentoxifylline and intermittent claudication: critical analysis of clinical trials]. Therapie. 1995;50(1):73-8.
Charansonney, O. L., & Spriet, A. (1995). [Pentoxifylline and intermittent claudication: critical analysis of clinical trials]. Therapie, 50(1), 73-8.
Charansonney OL, Spriet A. [Pentoxifylline and Intermittent Claudication: Critical Analysis of Clinical Trials]. Therapie. 1995 Jan-Feb;50(1):73-8. PubMed PMID: 7754482.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Pentoxifylline and intermittent claudication: critical analysis of clinical trials]. AU - Charansonney,O L, AU - Spriet,A, PY - 1995/1/1/pubmed PY - 1995/1/1/medline PY - 1995/1/1/entrez SP - 73 EP - 8 JF - Therapie JO - Therapie VL - 50 IS - 1 N2 - Drug utility in the treatment of intermittent claudication is controversial, mainly because of data heterogeneity and not too obvious benefit in the clinical trials. Pentoxifylline is the world's largest prescribed drug for intermittent claudication. In an attempt to define its benefit in the global care of the claudicants, we have analysed all the randomized double-blind, placebo-controlled trials listed from the international data-bases. Methodology of these trials have been compared with the European and FDA guidelines. In this respect, the 3 best suitable studies are consistent with one other and with a statistical benefit of pentoxifylline on the claudication distances. Although this effect is not truly predictive of the long term benefit-risk ratio of the drug, it seems clinically useful, especially when considering stable patients and when using the drug after previous physical training. SN - 0040-5957 UR - https://www.unboundmedicine.com/medline/citation/7754482/[Pentoxifylline_and_intermittent_claudication:_critical_analysis_of_clinical_trials]_ L2 - https://medlineplus.gov/clinicaltrials.html DB - PRIME DP - Unbound Medicine ER -